Home  /  Resource Library  /  Involved-site radiotherapy is equally effective and less toxic than Involved-field radiotherapy in patients receiving combined modality treatment for early-stage unfavorable Hodgkin lymphoma – an analysis of the randomized phase III HD17 trial of the German Hodgkin Study Group

Involved-site radiotherapy is equally effective and less toxic than Involved-field radiotherapy in patients receiving combined modality treatment for early-stage unfavorable Hodgkin lymphoma – an analysis of the randomized phase III HD17 trial of the German Hodgkin Study Group

Study investigated radiation therapy in the treatment of Hodgkin lymphoma.